Experience of clinical use of non-hormonal cream Triofemin to control the symptoms of genitourinary syndrome of menopause/vulvovaginal atrophy in peri- and postmenopausal patients
Ermakova E.I., Smetnik A.A., Ivanov I.A.
Objective: To evaluate the efficacy of a non-hormonal cream containing hyaluronic acid, a phytocomplex, and lactobacilli in peri- and postmenopausal women for the treatment of genitourinary syndrome of menopause/vulvovaginal atrophy (GSM/VVA) symptoms.
Materials and methods: This observational prospective study included 40 patients aged 46 to 75 with GSM/VVA symptoms. During the screening visit, after the examination, the women received a non-hormonal cream containing hyaluronic acid, a phytocomplex and lactobacilli, according to the following scheme: one dose applied vaginally at night daily for four weeks, then one dose applied three times a week for eight weeks. The efficacy and safety of the treatment were assessed after one and three months using a 4-point VAS scale, a vaginal health index (VHI), pH-meters, vaginal microbiome status, and adverse event diaries.
Results: Of the 40 participants, 34 completed the 12-week treatment course and follow-up period. The use of the non-hormonal cream Triofemin in patients with GSM/VVA for three months led to a significant decrease in the severity of subjective symptoms (dryness, dyspareunia, burning, irritation and pain) by 2.2 times compared with the baseline data (initial VAS score was 10.21, after three months it was 4.62, p<0.001). There was a significant improvement in the objective signs of VVA and a 2-fold increase in the VHI compared with the baseline values (initial VHI was 9.06, after three months it was 18.26, p<0.001). Moreover, there was a significant decrease in vaginal pH during treatment (initial pH was 5.71, after three months of therapy it was 5.18, p<0.05), an increase in the amount of lactoflora in the vaginal biotope by 1.8 times (initially average % of total bacterial mass was 28.56, after three months of therapy it was 51.63) and a decrease by almost 2 times of facultative anaerobic microorganisms (initially average % of total bacterial mass was 19.37%, after three months it was 9.75%) and obligate anaerobic microorganisms (initially average % of total bacterial mass was 37.24%, after three months it was 18.31%).
Conclusion: The obtained results demonstrate the good efficacy and tolerability of the non-hormonal cream Triofemin. This product can be recommended to patients with GSM, including those groups of patients who have contraindications or limitations to the use of topical estrogens.
Authors’ contributions: Ermakova E.I., Smetnik A.A., Ivanov I.A.: developing the concept and design of the study, collecting and processing the material, writing the text, editing the article.
Conflicts of interest: The authors declare no possible conflicts of interest.
Funding: The study was conducted without sponsorship.
Ethical Approval: The study was approved by the Ethical Review Board of the Academician V.I. Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology, Ministry of Health of Russia.
Patient Consent for Publication: The patients signed informed consent for the publication of their data.
Authors' Data Sharing Statement: The data supporting the findings of this study are available on request from the corresponding author after approval from the principal investigator.
For citation: Ermakova E.I., Smetnik A.A., Ivanov I.A. Experience of clinical use of non-hormonal cream Triofemin to control the symptoms of genitourinary syndrome of menopause/vulvovaginal atrophy in peri- and postmenopausal patients.
Akusherstvo i Ginekologiya/Obstetrics and Gynecology. 2026; (2): 128-138 (in Russian)
https://dx.doi.org/10.18565/aig.2026.27
Keywords
perimenopause
urogenital disorders
vulvovaginal atrophy
genitourinary syndrome of menopause
vaginal dryness
dyspareunia
lubricants
References
- Donders G., Akinosoglou K., Massie Z., Özçelik S. Review of current and emerging estrogen receptor agonists for vaginal atrophy. Expert Opin. Pharmacother. 2025; 26(3): 249-55. https://dx.doi.org/10.1080/14656566.2025.2451150
- Portman D.J., Gass M.L.S. Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the study of Woman’s Sexual Health and The North American Menopause Society, on behalf of the Vulvovaginal Atrophy Terminology Consensus Conference Panel. Maturitas. 2014; 79(3): 349-54. https://dx.doi.org/10.1016/j.maturitas.2014.07.013
- Palacios S., Castelo-Branco C., Currie H., Mijatovic V., Nappi R.E., Simon J. et al. Update on management of genitourinary syndrome of menopause: a practical guide. Maturitas. 2015; 82(3): 308-13. https://dx.doi.org/10.1016/j.maturitas.2015.07.020
- The NAMS 2020 GSM Position Statement Editorial Panel. The 2020 genitourinary syndrome of menopause position statement of The North American Menopause Society. Menopause. 2020; 27(9): 976-92. https://dx.doi.org/10.1097/GME.0000000000001609
- Зиганшина Л.З., Муслимова С.Ю., Сахаутдинова И.В., Зулкарнеева Э.М. Симптомы и клиника постменопаузальной вульвовагинальной атрофии в различные стадии постменопаузы. Гинекология. 2023; 25(2): 153-7. [Ziganshina L.Z., Muslimova S.Yu., Sakhautdinova I.V., Zulkarneeva E.M. Symptoms and clinic of postmenopausal vulvovaginal atrophy in different stages of postmenopause: a cross sectional study. Gynecology. 2023; 25(2): 153-7 (in Russian)]. https://dx.doi.org/10.26442/20795696.2023.2.202132
- Nappi R.E., Kokot-Kierepa M. Women's voices in the menopause: results from an international survey on vaginal atrophy. Maturitas. 2010; 67(3): 233-8. https://dx.doi.org/10.1016/j.maturitas.2010.08.001
- Kasano J.P.M., Crespo H.F.G., Arias R.A.R., Alamo I. Genitourinary syndrome in menopause: impact of vaginal symptoms. Turk. J. Obstet. Gynecol. 2023; 20(1): 38-45. https://dx.doi.org/10.4274/tjod.galenos.2023.50449
- Lethaby A., Ayeleke R.O., Roberts H. Local oestrogen for vaginal atrophy in postmenopausal women. Cochrane Database Syst. Rev. 2016; 2016(8): CD001500. https://dx.doi.org/10.1002/14651858.CD001500.pub3
- Rueda C., Osorio A.M., Avellaneda A.C., Pinzón C.E., Restrepo O.I. The efficacy and safety of estriol to treat vulvovaginal atrophy in postmenopausal women: a systematic literature review. Climacteric. 2017; 20(4): 321-30. https://dx.doi.org/10.1080/13697137.2017.1329291
- Hirschberg A.L., Bitzer J., Cano A., Ceausu I., Chedraui P., Durmusoglu F. et al. Topical estrogens and non-hormonal preparations for postmenopausal vulvovaginal atrophy: an EMAS clinical guide. Maturitas. 2021; 148: 55-61. https://dx.doi.org/10.1016/j.maturitas.2021.04.005
- “The 2022 Hormone Therapy Position Statement of The North American Menopause Society” Advisory Panel. The 2022 hormone therapy position statement of The North American Menopause Society. Menopause. 2022; 29(7): 767-94. https://dx.doi.org/10.1097/GME.0000000000002028
- Министерство здравоохранения Российской Федерации. Клинические рекомендации. Менопауза и климактерическое состояние у женщины. 2025. [Ministry of Health of the Russian Federation. Clinical guidelines. Menopause and menopausal syndrome in women. 2025 (in Russian)].
- Cui Y., Zong H., Yan H., Li N., Zhang Y. The efficacy and safety of ospemifene in treating dyspareunia associated with postmenopausal vulvar and vaginal atrophy: a systematic review and meta-analysis. J. Sex. Med. 2014; 11(2): 487-97. https://dx.doi.org/10.1111/jsm.12377
- Di Carlo C., Cagnacci A., Murina F., Maffei S., Becorpi A., Lello S. Ospemifene and vulvovaginal atrophy: an update of the clinical profile for post-menopausal women. Expert Opin. Pharmacother. 2024; 25(11): 1541-54. https://dx.doi.org/10.1080/14656566.2024.2391009
- Labrie F., Archer D.F., Bouchard C., Girard G., Ayotte N., Gallagher J.C. et al. Prasterone has parallel beneficial effects on the main symptoms of vulvovaginal atrophy: 52-week open-label study. Maturitas 2015; 81(1): 46-56. https://dx.doi.org/10.1016/j.maturitas.2015.02.005
- Bouchard C., Labrie F., Derogatis L., Girard G., Ayotte N., Gallagher J. et al. Effect of intravaginal dehydroepiandrosterone (DHEA) on the female sexual function in postmenopausal women: ERC-230 open-label study. Horm. Mol. Biol. Clin. Investig. 2016; 25(3): 181-90. https://dx.doi.org/10.1515/hmbci-2015-0044
- Юренева С.В., Ермакова Е.И. Менопауза и климактерическое состояние у женщины. Акушерство и гинекология. 2018; 7: 32-8. [Yureneva S.V., Ermakova E.I. Menopause and menopause in women. Obstetrics and Gynecology. 2018; (7): 32-8 (in Russian)]. https://dx.doi.org/10.18565/aig.2018.7.32-38
- Nappi R.E., Baber R. What is in a name? A decade after changing from VVA to GSM have we come any closer to ending the 'silent suffering' of postmenopausal women with genitourinary symptoms? Climacteric. 2023; 26(4): 289-91. https://dx.doi.org/10.1080/13697137.2023.2225323
- World Health Organization. Use and procurement of additional lubricants for male and female condoms: WHO/UNFPA/FHI360: advisory note. 2012. https://iris.who.int/handle/10665/76580
- Eaton A.A., Baser R.E., Seidel B., Stabile C., Canty J.P., Goldfrank D.J. et al. Validation of clinical tools for vaginal and vulvar symptom assessment in cancer patients and survivors. J. Sex. Med. 2017; 14(1): 144-51. https://dx.doi.org/10.1016/j.jsxm.2016.11.317
- Bachmann G. Urogenital ageing: an old problem newly recognized. Maturitas. 1995; 22(Suppl): S1-S5. https://dx.doi.org/10.1016/0378-5122(95)00956-6
Received 29.01.2026
Accepted 04.02.2026
About the Authors
Elena I. Ermakova, PhD, Senior Researcher, Academician V.I. Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology, Ministry of Healthcare of Russian Federation, 117997, Russia, Moscow, Oparin str., 4; Vice-President of Russian Menopause Society, +7(916)848-37-46, ermakova.health@mail.ru,https://orcid.org/0000-0002-6629-051X
Аntonina А. Smetnik, PhD, Head of the Department of Gynecological Endocrinology, Associate Professor at the Department of Obstetrics and Gynecology, Institute of Postgraduate Education, V.I. Kulakov National Medical Research Center for Obstetrics and Gynecology, Ministry of Health of Russia, 117997, Russia, Moscow, Oparin str., 4; President of the Russian Society of Specialists in Gynecological Endocrinology and Menopause (ROSGEM), +7(495)531-44-44, a_smetnik@oparina4.ru,
https://orcid.org/0000-0002-0627-3902
Ilya A. Ivanov, PhD, Researcher, Department of Gynecological Endocrinology, V.I. Kulakov National Medical Research Center for Obstetrics and Gynecology,
Ministry of Health of Russia, 117997, Russia, Moscow, Oparin str., 4, +7(962)980-00-18, doctor.i.ivanov@yandex.ru https://orcid.org/0000-0003-0751-7566
Similar Articles
